Abstract
Current treatment approaches for hepatocellular carcinoma (HCC) have a narrow therapeutic index and alternate modes of treatment are thus required. We have utilized a gene delivery vector containing inducible caspase 9 (iCasp9) gene, which is a synthetic analogue based on the mammalian caspase 9 and fused to a human FK506 binding protein that allows its conditional dimerization to a synthetic, small molecule [chemical inducer of dimerization, AP20187] and results in target cell apoptosis. In our studies, we have tested these synthetic vectors based on an adeno-associated virus platform for their potential anti-tumorigenic effect in human HCC cells in vitro and in a HCC tumor model developed in nude mice. Our data demonstrates that the iCasp9-AP20187 bioconjugate is able to trigger terminal effectors of cellular apoptosis and presents a viable approach for the potential treatment of HCC.
Highlights
Hepatocellular carcinoma (HCC) is a malignancy of the liver
An inducible caspase 9 gene, which is a synthetic analogue based on the mammalian caspase 9 fused to a human FK506 binding protein (FKBP) that allows conditional dimerization to a synthetic, bioinert small molecule [chemical inducer of dimerization (CID), AP20187], has been tested to switch-off genes during T cell therapy.[22,23] iCasp[9] is nonimmunogenic, since apart from a single amino acid substitution
In order to further characterize the tumor regression at the molecular level, in response to inducible caspase 9 (iCasp9)/AP20187 treatment, a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL, Roche, Basel, Switzerland) assay was performed. This test detects DNA strand break in cells undergoing apoptosis and has been used widely as a biomarker for diagnostic evaluation of apoptosis along with caspase-3.39,40 Our screening revealed that tumor tissue from the iCasp9/ AP20187 treated group were markedly positive for TUNEL staining signifying massive cell death as compared to the tumor tissue harvested from the control group
Summary
Hepatocellular carcinoma (HCC) is a malignancy of the liver. About 600,000 new cases of HCC are reported annually, making it the fifth most common cause of all cancers affecting humans.[1−3] The mortality of this condition is very high; approximately 250,000 deaths occur annually due to HCC.[3]. These data indicate that the rate of tumor attenuation was slightly reduced in the low dose group (1 mg/kg body weight) as compared to animals that received a higher dose (2 mg/kg bodyweight) of AP20187 (Figure 3). In order to further characterize the tumor regression at the molecular level, in response to iCasp9/AP20187 treatment, a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL, Roche, Basel, Switzerland) assay was performed This test detects DNA strand break in cells undergoing apoptosis and has been used widely as a biomarker for diagnostic evaluation of apoptosis along with caspase-3.39,40 Our screening revealed that tumor tissue from the iCasp9/ AP20187 treated group were markedly positive for TUNEL staining (red color) signifying massive cell death as compared to the tumor tissue harvested from the control group
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have